716 related articles for article (PubMed ID: 25966339)
1. Efficacy and Safety of Antiretroviral Therapy Initiated One Week after Tuberculosis Therapy in Patients with CD4 Counts < 200 Cells/μL: TB-HAART Study, a Randomized Clinical Trial.
Amogne W; Aderaye G; Habtewold A; Yimer G; Makonnen E; Worku A; Sonnerborg A; Aklillu E; Lindquist L
PLoS One; 2015; 10(5):e0122587. PubMed ID: 25966339
[TBL] [Abstract][Full Text] [Related]
2. Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial.
Bonnet M; Bhatt N; Baudin E; Silva C; Michon C; Taburet AM; Ciaffi L; Sobry A; Bastos R; Nunes E; Rouzioux C; Jani I; Calmy A;
Lancet Infect Dis; 2013 Apr; 13(4):303-12. PubMed ID: 23433590
[TBL] [Abstract][Full Text] [Related]
3. Time to initiate antiretroviral therapy between 4 weeks and 12 weeks of tuberculosis treatment in HIV-infected patients: results from the TIME study.
Manosuthi W; Mankatitham W; Lueangniyomkul A; Thongyen S; Likanonsakul S; Suwanvattana P; Thawornwan U; Suntisuklappon B; Nilkamhang S; Sungkanuparph S;
J Acquir Immune Defic Syndr; 2012 Aug; 60(4):377-83. PubMed ID: 22592586
[TBL] [Abstract][Full Text] [Related]
4. Development of opportunistic infections after diagnosis of active tuberculosis in HIV-infected patients.
Kwara A; Carter EJ; Rich JD; Flanigan TP
AIDS Patient Care STDS; 2004 Jun; 18(6):341-7. PubMed ID: 15294084
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of once-daily nevirapine- or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trial.
Swaminathan S; Padmapriyadarsini C; Venkatesan P; Narendran G; Ramesh Kumar S; Iliayas S; Menon PA; Selvaraju S; Pooranagangadevi NP; Bhavani PK; Ponnuraja C; Dilip M; Ramachandran R
Clin Infect Dis; 2011 Oct; 53(7):716-24. PubMed ID: 21890776
[TBL] [Abstract][Full Text] [Related]
6. Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial.
Grinsztejn B; De Castro N; Arnold V; Veloso VG; Morgado M; Pilotto JH; Brites C; Madruga JV; Barcellos NT; Santos BR; Vorsatz C; Fagard C; Santini-Oliveira M; Patey O; Delaugerre C; Chêne G; Molina JM;
Lancet Infect Dis; 2014 Jun; 14(6):459-67. PubMed ID: 24726095
[TBL] [Abstract][Full Text] [Related]
7. Prevention of Early Mortality by Presumptive Tuberculosis Therapy Study: An Open Label, Randomized Controlled Trial.
Manabe YC; Worodria W; van Leth F; Mayanja-Kizza H; Traore AN; Ferro J; Pakker N; Frank M; Grobusch MP; Colebunders R; Cobelens F
Am J Trop Med Hyg; 2016 Dec; 95(6):1265-1271. PubMed ID: 27928077
[TBL] [Abstract][Full Text] [Related]
8. Impaired CD4 T-cell count response to combined antiretroviral therapy in antiretroviral-naive HIV-infected patients presenting with tuberculosis as AIDS-defining condition.
Cingolani A; Cozzi Lepri A; Castagna A; Goletti D; De Luca A; Scarpellini P; Fanti I; Antinori A; d'Arminio Monforte A; Girardi E
Clin Infect Dis; 2012 Mar; 54(6):853-61. PubMed ID: 22157323
[TBL] [Abstract][Full Text] [Related]
9. Integration of antiretroviral therapy with tuberculosis treatment.
Abdool Karim SS; Naidoo K; Grobler A; Padayatchi N; Baxter C; Gray AL; Gengiah T; Gengiah S; Naidoo A; Jithoo N; Nair G; El-Sadr WM; Friedland G; Abdool Karim Q
N Engl J Med; 2011 Oct; 365(16):1492-501. PubMed ID: 22010915
[TBL] [Abstract][Full Text] [Related]
10. Early versus delayed initiation of highly active antiretroviral therapy for HIV-positive adults with newly diagnosed pulmonary tuberculosis (TB-HAART): a prospective, international, randomised, placebo-controlled trial.
Mfinanga SG; Kirenga BJ; Chanda DM; Mutayoba B; Mthiyane T; Yimer G; Ezechi O; Connolly C; Kapotwe V; Muwonge C; Massaga J; Sinkala E; Kohi W; Lyantumba L; Nyakoojo G; Luwaga H; Doulla B; Mzyece J; Kapata N; Vahedi M; Mwaba P; Egwaga S; Adatu F; Pym A; Joloba M; Rustomjee R; Zumla A; Onyebujoh P
Lancet Infect Dis; 2014 Jul; 14(7):563-71. PubMed ID: 24810491
[TBL] [Abstract][Full Text] [Related]
11. Incidence of tuberculosis and early mortality in a large cohort of HIV infected patients receiving antiretroviral therapy in a tertiary hospital in Addis Ababa, Ethiopia.
Kassa A; Teka A; Shewaamare A; Jerene D
Trans R Soc Trop Med Hyg; 2012 Jun; 106(6):363-70. PubMed ID: 22521216
[TBL] [Abstract][Full Text] [Related]
12. Treatment outcomes after early initiation of antiretroviral therapy for human immunodeficiency virus-associated tuberculosis.
Chan CK; Wong KH; Leung CC; Tam CM; Chan KC; Pang KW; Chan WK; Mak IK
Hong Kong Med J; 2013 Dec; 19(6):474-83. PubMed ID: 23926173
[TBL] [Abstract][Full Text] [Related]
13. Management of individuals requiring antiretroviral therapy and TB treatment.
Cohen K; Meintjes G
Curr Opin HIV AIDS; 2010 Jan; 5(1):61-9. PubMed ID: 20046149
[TBL] [Abstract][Full Text] [Related]
14. A randomized trial of punctuated antiretroviral therapy in Ugandan HIV-seropositive adults with pulmonary tuberculosis and CD4⁺ T-cell counts of ≥ 350 cells/μL.
Nanteza MW; Mayanja-Kizza H; Charlebois E; Srikantiah P; Lin R; Mupere E; Mugyenyi P; Boom WH; Mugerwa RD; Havlir DV; Whalen CC
J Infect Dis; 2011 Sep; 204(6):884-92. PubMed ID: 21849285
[TBL] [Abstract][Full Text] [Related]
15. Earlier initiation of antiretroviral therapy, increased tuberculosis case finding and reduced mortality in a setting of improved HIV care: a retrospective cohort study.
Hermans SM; van Leth F; Manabe YC; Hoepelman AI; Lange JM; Kambugu A
HIV Med; 2012 Jul; 13(6):337-44. PubMed ID: 22296211
[TBL] [Abstract][Full Text] [Related]
16. Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trial.
Hosseinipour MC; Bisson GP; Miyahara S; Sun X; Moses A; Riviere C; Kirui FK; Badal-Faesen S; Lagat D; Nyirenda M; Naidoo K; Hakim J; Mugyenyi P; Henostroza G; Leger PD; Lama JR; Mohapi L; Alave J; Mave V; Veloso VG; Pillay S; Kumarasamy N; Bao J; Hogg E; Jones L; Zolopa A; Kumwenda J; Gupta A;
Lancet; 2016 Mar; 387(10024):1198-209. PubMed ID: 27025337
[TBL] [Abstract][Full Text] [Related]
17. Effect of immediate initiation of antiretroviral therapy on risk of severe bacterial infections in HIV-positive people with CD4 cell counts of more than 500 cells per μL: secondary outcome results from a randomised controlled trial.
O'Connor J; Vjecha MJ; Phillips AN; Angus B; Cooper D; Grinsztejn B; Lopardo G; Das S; Wood R; Wilkin A; Klinker H; Kantipong P; Klingman KL; Jilich D; Herieka E; Denning E; Abubakar I; Gordin F; Lundgren JD;
Lancet HIV; 2017 Mar; 4(3):e105-e112. PubMed ID: 28063815
[TBL] [Abstract][Full Text] [Related]
18. Paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome after early initiation of antiretroviral therapy in a randomized clinical trial.
Laureillard D; Marcy O; Madec Y; Chea S; Chan S; Borand L; Fernandez M; Prak N; Kim C; Dim B; Nerrienet E; Sok T; Delfraissy JF; Goldfeld AE; Blanc FX;
AIDS; 2013 Oct; 27(16):2577-86. PubMed ID: 24096631
[TBL] [Abstract][Full Text] [Related]
19. [Impact of etiotropic therapy on the immune status of patients with HIV infection and tuberculosis].
Zimina VN; Kravchenko AV
Ter Arkh; 2015; 87(11):37-41. PubMed ID: 26821414
[TBL] [Abstract][Full Text] [Related]
20. Algorithm-guided empirical tuberculosis treatment for people with advanced HIV (TB Fast Track): an open-label, cluster-randomised trial.
Grant AD; Charalambous S; Tlali M; Karat AS; Dorman SE; Hoffmann CJ; Johnson S; Vassall A; Churchyard GJ; Fielding KL
Lancet HIV; 2020 Jan; 7(1):e27-e37. PubMed ID: 31727580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
